Now in its fourth edition, the guideline offers greater clarity, structure, and inclusivity, particularly with the addition of digital medical devices.
For developers, manufacturers, and sponsors of innovative medical products, understanding this guideline is critical to navigating Korea’s regulatory framework efficiently and strategically.
Purpose of the Guideline
The MFDS pre-consultation program is designed to facilitate early-stage dialogue between product developers and regulators.
By engaging with MFDS during the development phase, companies can:
I. Gain early clarity on regulatory expectations
II. Identify appropriate classification and pathways
III. Reduce risks in product development
IV. Streamline the clinical trial and approval process
The guideline serves as a foundational tool for aligning product development with South Korea’s regulatory standards, ultimately accelerating time to market and improving compliance outcomes.
Scope of the Guideline
The guideline applies to a broad range of innovative medical products, including:
- New and emerging medical devices
- Regenerative medical products
- Biopharmaceuticals and advanced therapies
- Combination products
- Digital medical devices (added in this 4th revision)
These product types often present unique scientific, clinical, or regulatory challenges that may not fit neatly into existing pathways. The pre-consultation process offers a forum to address these issues collaboratively.
What’s New in the 4th Revision (June 2025)
The 4th revision introduces key updates that reflect evolving technologies and the MFDS’s intent to promote innovation while maintaining regulatory compliance.
Inclusion of Digital Medical Devices
For the first time, the guideline explicitly includes digital medical technologies, such as:
- Software as a Medical Device (SaMD)
- AI-based diagnostic tools
- Mobile health applications
This update follows the recent enactment of the Digital Medical Products Act, signaling South Korea’s commitment to integrating digital health into its regulatory framework. Developers of digital health solutions now have a formal mechanism for early-stage consultation with MFDS, improving predictability and aligning product development with current laws.
Clarification of Roles and Responsibilities
To improve coordination and reduce ambiguity, the updated guideline outlines which MFDS departments are responsible for various product types.
For example:
- Biopharmaceuticals are handled by the Office of New Drug Review
- Regenerative therapies may involve both biologicals and device divisions
- Combination products will be jointly assessed by relevant units
This organizational clarity helps applicants direct inquiries to the correct department, reducing processing delays and improving communication.
Enhanced Consultation Process Details
The revised guideline also provides greater transparency into how consultations unfold, including:
- Step-by-step procedures from request to response
- Expected timelines for each phase of the consultation
- Required documentation at submission
- MFDS response structure, including issuance of non-binding written opinions
By clearly defining these parameters, the MFDS aims to make the pre-consultation process more accessible, consistent, and efficient.
Pre-Consultation Procedure Overview
The MFDS pre-consultation process consists of four core stages:
I. Request Submission: Applicants (typically manufacturers, developers, or sponsorS) submit a pre-consultation request that includes:
- A completed application form
- A summary of the product and its intended use
- A development plan outlining the product’s stage and projected milestones
II. Eligibility Screening: MFDS assesses whether the product qualifies as “innovative” and whether it is at an appropriate development stage for meaningful consultation. Factors considered include novelty, therapeutic value, and potential regulatory challenges.
III. Consultation Meeting: If accepted, a meeting is arranged either in-person or virtually with MFDS reviewers from relevant departments.
Key discussion topics may include:
- Product classification
- Applicable regulatory pathways
- Preclinical and clinical trial expectations
- Risk management and safety data requirements
These consultations are not approvals but provide valuable insight into MFDS’s expectations.
IV. Issuance of Written Feedback: MFDS provides a written summary of the consultation. While non-binding, this guidance can help shape future regulatory submissions and development strategies.
The feedback may include:
- Confirmation of classification
- Recommendations for evidence development
- Insights on submission timelines and documentation
Benefits of Pre-Consultation
Engaging in pre-consultation can offer significant strategic advantages:
- Early identification of regulatory requirements allows developers to build compliant processes from the start.
- Reduced risk of delays during product review by resolving ambiguities ahead of formal submission.
- Faster time to market, as clinical and technical requirements can be anticipated and addressed early.
- Improved collaboration with MFDS, fostering mutual understanding and smoother review cycles.
For high-risk or novel products, such as AI tools or cell-based therapies, the ability to validate assumptions and receive preliminary feedback is particularly valuable.
Conclusion
South Korea’s 4th revision of the Guidelines on Pre-Consultation for Innovative Products marks a significant milestone in the country’s regulatory modernization. By incorporating digital medical technologies and providing greater procedural clarity, the MFDS strengthens its support for innovation while maintaining high standards for safety and effectiveness.
Developers are strongly encouraged to leverage this structured pre-consultation pathway not just as a compliance exercise, but as a strategic asset in product development. As regulatory expectations grow more complex, early and informed engagement with health authorities becomes essential to staying competitive in the global market.
Whether you’re introducing a novel biologic, a regenerative therapy, or a cutting-edge digital solution, South Korea’s pre-consultation process offers a critical opportunity to align innovation with regulatory success.
Source
How Can RegDesk Help?
RegDesk is an AI-powered Regulatory Information Management System (RIMS) designed to simplify global compliance for medical device companies. With regulatory intelligence covering 120+ markets, RegDesk helps you prepare and publish global submissions, manage standards, conduct impact assessments, and stay ahead of regulatory changes all from a single, centralized platform. Expanding into new markets has never been easier.
